Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tazeen Idris"'
Autor:
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz:
https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Autor:
Joel Owen, Cornelius F. Waller, Hope S. Rugo, Abhijit Barve, Adolfo Fuentes-Alburo, Russell J. Rackley, Tazeen Idris, Subramanian Loganathan, Mark Liu
Publikováno v:
Cancer Research. 81:PS18-23
Background: Mylan trastuzumab (MYL-1401O) is a biosimilar to trastuzumab (Herceptin®). A multicenter, double blind, randomized, phase III study (HERITAGE) compared the efficacy, safety, Pop PK and immunogenicity of MYL-1401O and trastuzumab in patie
Autor:
Mark A. Socinski, Matthew A. Hummel, Cornelius F. Waller, Russell J. Rackley, Tazeen Idris, Joel Owen, Sundara Moorthi Nainar Murugesan, Gopinath Ranganna, Mark Liu, Stefan Roepcke, Ashwini Vishweswaramurthy, Hannah Huang, Abhijit Barve, Subramanian Loganathan
Publikováno v:
Journal of Clinical Oncology. 39:e21087-e21087
e21087 Background: MYL-1402O (MYL) is a proposed biosimilar to bevacizumab reference product. A multicenter, double blind randomized, phase 3 study compared the efficacy, safety, PK, and immunogenicity of MYL and Avastin in patients with Stage IV met
Autor:
Cornelius F. Waller, Mark A. Socinski, Igor Bondarenko, Vivek G Nayak, Melody Woods, Matthew A. Hummel, Ashwini Vishweswaramurthy, Gopinath Ranganna, Roxann Shapiro, Katrin Beckmann, Subramanian Loganathan, Tazeen Idris, Anita Rao, Alexander Luft, Abhijit Barve, Charles Donnelly
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien